EP Patent

EP2222667B1 — Novel thiophene derivatives as agonists of s1p1/edg1

Assigned to Actelion Pharmaceuticals Ltd · Expires 2013-02-20 · 13y expired

What this patent protects

Patent listed against ozanimod-hydrochloride.

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: EP2222667B1
Jurisdiction: EP
Classification: —
Expires: 2013-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.